RGEN

+ Watchlist + Portfolio

Repligen Corp.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $177.23
52-Week Range: $100.99 – $198.87
Market Cap: $10.25B
P/E (TTM): 248.90
EPS (TTM): 0.73
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 4.85
PEG Ratio: 1.81
Return on Equity: 1.99%
Return on Assets: 1.40%
Gross Margin: 53.84%
Operating Margin: 9.31%
Profit Margin: 5.29%
Current Ratio: 9.05
Debt/Equity: 0.33
Total Debt: $690.94M
Free Cash Flow: $113.42M
Revenue Growth: 11.90%
Earnings Growth: -65.90%
Enterprise Value: $10.13B

RGEN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$801.54M	$632.36M	$634.44M	$738.26M
Cost of Revenue	$345.83M	$353.92M	$359.79M	$352.01M
Gross Profit	$455.71M	$278.44M	$274.64M	$386.25M
Research & Development	$43.94M	$42.72M	$43.20M	$54.18M
Selling, General & Admin	$215.83M	$218.58M	$263.37M	$290.51M
Operating Expenses	$259.76M	$261.31M	$306.57M	$344.69M
Operating Income	$195.94M	$17.13M	-$31.92M	$41.56M
EBITDA	$277.31M	$145.32M	$80.26M	$180.85M
Pretax Income	$219.14M	$56.71M	-$27.04M	$62.38M
Income Tax	$33.18M	$21.11M	-$1.52M	$13.49M
Net Income	$185.96M	$35.60M	-$25.51M	$48.89M
Diluted EPS	3.24	0.74	-0.46	0.86
Diluted Shares	57.46M	56.38M	55.94M	56.56M

RGEN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$523.46M	$751.32M	$757.36M	$566.02M
Receivables	$116.25M	$124.16M	$134.12M	$158.59M
Inventory	$238.28M	$202.32M	$142.96M	$170.46M
Current Assets	$998.12M	$1.11B	$1.07B	$1.14B
Total Assets	$2.53B	$2.83B	$2.83B	$2.95B
Current Liabilities	$404.20M	$164.94M	$126.79M	$135.83M
Long-Term Debt	—	$510.14M	$525.57M	$542.21M
Total Debt	$422.96M	$711.80M	$686.25M	$689.95M
Total Liabilities	$620.90M	$866.34M	$856.95M	$843.57M
Retained Earnings	$397.27M	$432.87M	$407.35M	$456.25M
Shareholders' Equity	$1.91B	$1.96B	$1.97B	$2.11B
Working Capital	$593.92M	$946.40M	$939.25M	$1.00B

RGEN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$172.08M	$113.92M	$175.39M	$117.42M
Capital Expenditure	-$133.35M	-$38.99M	-$32.91M	-$25.73M
Free Cash Flow	$38.74M	$74.93M	$142.49M	$91.69M
Depreciation & Amortisation	$57.01M	$86.11M	$86.56M	$96.96M
Stock-Based Compensation	$27.32M	$25.57M	$48.07M	$32.60M
Investing Cash Flow	-$233.24M	-$123.28M	-$86.38M	-$298.47M
Financing Cash Flow	-$13.34M	$248.96M	-$82.90M	-$15.21M
Share Repurchases	$0.00	-$14.39M	$0.00	$0.00
Net Change in Cash	-$74.49M	$239.60M	$6.11M	-$196.26M

RGEN Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$182.37M	$188.81M	$197.91M	$194.25M	$204.13M
Cost of Revenue	$89.37M	$88.29M	$94.08M	$85.97M	$94.09M
Gross Profit	$93.00M	$100.52M	$103.83M	$108.28M	$110.04M
Research & Development	$13.97M	$14.18M	$13.12M	$14.46M	$14.42M
Selling, General & Admin	$70.91M	$73.66M	$74.36M	$76.54M	$76.62M
Operating Expenses	$84.88M	$87.84M	$87.48M	$90.99M	$91.03M
Operating Income	$8.12M	$12.68M	$16.35M	$17.29M	$19.00M
EBITDA	$48.34M	$46.94M	$49.20M	$31.89M	$43.59M
Pretax Income	$18.21M	$17.11M	$19.11M	$1.77M	$14.15M
Income Tax	$3.35M	$2.20M	$5.83M	-$6.56M	$9.14M
Net Income	$14.87M	$14.91M	$13.29M	$8.33M	$5.01M
Diluted EPS	0.26	0.26	0.23	0.15	0.09
Diluted Shares	56.51M	56.53M	56.66M	56.67M	56.64M

RGEN Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$708.86M	$748.75M	$566.02M	$582.65M	$606.78M
Receivables	$156.95M	$148.97M	$158.59M	$151.55M	$157.71M
Inventory	$155.86M	$160.32M	$170.46M	$179.26M	$186.60M
Current Assets	$1.06B	$1.10B	$1.14B	$1.16B	$1.20B
Total Assets	$2.90B	$2.92B	$2.95B	$2.93B	$2.95B
Current Liabilities	$123.01M	$131.14M	$135.83M	$126.21M	$132.66M
Long-Term Debt	$533.73M	$537.93M	$542.21M	$546.59M	$551.05M
Total Debt	$686.06M	$688.87M	$689.95M	$687.62M	$690.94M
Total Liabilities	$839.89M	$840.62M	$843.57M	$825.31M	$838.15M
Retained Earnings	$428.05M	$442.96M	$456.25M	$464.58M	$469.59M
Shareholders' Equity	$2.06B	$2.08B	$2.11B	$2.11B	$2.11B
Working Capital	$933.85M	$965.35M	$1.00B	$1.04B	$1.07B

RGEN Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$28.61M	$48.10M	$25.70M	$28.30M	$32.77M
Capital Expenditure	-$7.61M	-$5.39M	-$8.31M	-$4.95M	-$6.07M
Free Cash Flow	$21.00M	$42.71M	$17.39M	$23.35M	$26.70M
Depreciation & Amortisation	$24.77M	$24.41M	$24.59M	$24.54M	$23.77M
Stock-Based Compensation	$8.38M	$8.97M	$7.98M	$8.32M	$8.01M
Investing Cash Flow	-$7.84M	-$7.78M	-$208.74M	-$3.99M	-$2.09M
Financing Cash Flow	-$10.13M	-$239.00K	$195.00K	-$5.54M	-$6.20M
Net Change in Cash	$10.64M	$40.08M	-$182.84M	$18.76M	$24.48M

Market Snapshot

About

Repligen Corporation is a life sciences company providing bioprocessing equipment and consumables for the biopharmaceutical industry. Repligen manufactures filtration systems, chromatography products, process analytics, and proteins used in the production of biologics and cell and gene therapies. The company serves biomanufacturers worldwide with products critical to drug development and commercial production.